Evolving chemotherapeutics

Detsamma and FivepHusion to begin bridging clinical trial for Deflexifol.

Detsamma Investments and its partner FivepHusion have received human ethics approval to begin its bridging PK study of Deflexifol. This study will gather improved PK data and further efficacy signals in a regimen that matches SOC for 5-FU and Leucovorin.